- Home
- PGEN vs HYT Comparison
PGEN vs HYT Comparison
Compare PGEN & HYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PGEN | HYT |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | PGEN | HYT |
|---|---|---|
| Price | $3.81 | $8.60 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $8.33 | N/A |
| AVG Volume (30 Days) | ★ 4.0M | 732.2K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.61% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $230,981,000.00 | N/A |
| Revenue This Year | $1,115.92 | N/A |
| Revenue Next Year | $81.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.30 | $8.22 |
| 52 Week High | $5.47 | $9.88 |
Technical Indicators
Market Signals| Indicator | PGEN | HYT |
|---|---|---|
| Relative Strength Index (RSI) | 38.10 | 50.03 |
| Support Level | $3.49 | $8.38 |
| Resistance Level | $4.40 | $8.70 |
| Average True Range (ATR) | 0.29 | 0.07 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 2.97 | 67.19 |
Price Performance
Historical ComparisonAbout PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
About HYT Blackrock Corporate High Yield Fund Inc.
BlackRock Corporate High Yield Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is to provide shareholders with current income. The trust's secondary investment objective is to provide shareholders with capital appreciation. Under Normal market conditions, the fund invests at least 80% of its net assets in high-yield securities of corporate issuers and derivatives that provide exposure to those securities or related market risk factors.